Dendritic Cells: The Long and Evolving Road towards Successful Targetability in Cancer.
Dendritic Cells: The Long and Evolving Road towards Successful Targetability in Cancer.
复制标题
作者：
树突状细胞(DC)是一种独特的髓系细胞，在启动获得性免疫反应中发挥核心作用。因此，它们是基于免疫肿瘤学的治疗方法的一个有吸引力的靶点。然而，以这些细胞为靶点已被证明具有挑战性，许多研究证明在临床试验环境中没有定论或没有任何益处。在这篇综述中，我们重点介绍了关于这种罕见但强大的免疫细胞的已知和未知情况。随着技术的发展扩大了我们对DC发展、亚型和反应特征的复杂性的理解，我们现在只能将这些知识应用于癌症新治疗策略的设计。我们建议，通过多组学方法利用这些技术将允许在临床试验环境中改善DC的定向靶向。此外，DC研究界应该考虑在子集命名法上达成共识，以区分新的子集与其环境响应的功能或表型变化。
Dendritic cells (DCs) are a unique myeloid cell lineage that play a central role in the priming of the adaptive immune response. As such, they are an attractive target for immune oncology based therapeutic approaches. However, targeting these cells has proven challenging with many studies proving inconclusive or of no benefit in a clinical trial setting. In this review, we highlight the known and unknown about this rare but powerful immune cell. As technologies have expanded our understanding of the complexity of DC development, subsets and response features, we are now left to apply this knowledge to the design of new therapeutic strategies in cancer. We propose that utilization of these technologies through a multiomics approach will allow for an improved directed targeting of DCs in a clinical trial setting. In addition, the DC research community should consider a consensus on subset nomenclature to distinguish new subsets from functional or phenotypic changes in response to their environment.
登录
查看更多内容
影响因子：
7.4
作者：
Bailur, Jithendra Kini;Gueckel, Brigitte;Pawelec, Graham
通讯作者：
Pawelec, Graham
影响因子：
4.4
作者：
Andreae, S;Piras, F;Triebel, F
通讯作者：
Triebel, F
影响因子：
8
作者：
Bar, Noffar;Costa, Federica;Dhodapkar, Madhav V.
通讯作者：
Dhodapkar, Madhav V.
激动剂作为癌症治疗剂。
影响因子：
5.2
作者：
Amouzegar A;Chelvanambi M;Filderman JN;Storkus WJ;Luke JJ
通讯作者：
Luke JJ
影响因子：
8.8
作者：
Abiko, K.;Matsumura, N.;Hamanishi, J.;Horikawa, N.;Murakami, R.;Yamaguchi, K.;Yoshioka, Y.;Baba, T.;Konishi, I.;Mandai, M.
通讯作者：
Mandai, M.